NanoViricides Signs Agreement with University of Pittsburg for Ocular Testing of Its Drug Candidates

NanoViricides, Inc. (NYSEMKT:NNVC) has entered into an agreement with the University of Pittsburgh for the testing of its nanoviricides® drug candidates in standard animal models of ocular virus infections.
According to the press release:

The research will be performed in the Charles T. Campbell Ophthalmic Microbiology Laboratory by Dr. Eric Romanowski, Research Director. Dr. Romanowski has extensive experience in ocular virus infections and anti-viral agents discovery.

Eugene Seymour, MD, MPH, and CEO commented:

We are very pleased to have the Campbell Laboratory join our efforts in developing a drug against Herpes Keratitis. This is a renowned lab in the field of ocular infections with substantial experience in antiviral drugs development. We plan to perform IND-enabling efficacy studies of our anti-viral agents at the Campbell Labs.

Click here to view the full press release.